- Home
- Publications
- Publication Search
- Publication Details
Title
A Critical Review of the Efficacy and Safety of Inclisiran
Authors
Keywords
-
Journal
American Journal of Cardiovascular Drugs
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-05-06
DOI
10.1007/s40256-021-00477-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Targeting LDL cholesterol: Early treatment is key to population health
- (2020) Jane Stock ATHEROSCLEROSIS
- Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol
- (2020) Kausik K. Ray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia
- (2020) Frederick J. Raal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Low-density Lipoprotein-Cholesterol Lowering Strategies for Prevention of Atherosclerotic Cardiovascular Disease: Focus on siRNA Treatment Targeting PCSK9 (Inclisiran)
- (2020) David Sinning et al. Current Cardiology Reports
- Lipoprotein(a), PCSK9 Inhibition and Cardiovascular Risk: Insights from the FOURIER Trial
- (2019) Michelle L. O'Donoghue et al. CIRCULATION
- 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease
- (2019) Donna K. Arnett et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk
- (2019) François Mach et al. EUROPEAN HEART JOURNAL
- Effect of 1 or 2 Doses of Inclisiran on Low-Density Lipoprotein Cholesterol Levels
- (2019) Kausik K. Ray et al. JAMA Cardiology
- Inclisiran—New hope in the management of lipid disorders?
- (2019) Krzysztof Dyrbuś et al. Journal of Clinical Lipidology
- Effects of Renal Impairment on the Pharmacokinetics, Efficacy, and Safety of Inclisiran: An Analysis of the ORION-7 and ORION-1 Studies
- (2019) R. Scott Wright et al. MAYO CLINIC PROCEEDINGS
- Intensive LDL cholesterol-lowering treatment beyond current recommendations for the prevention of major vascular events: a systematic review and meta-analysis of randomised trials including 327 037 participants
- (2019) Nelson Wang et al. Lancet Diabetes & Endocrinology
- Role of PCSK9 in lipid metabolism and atherosclerosis
- (2018) Xiao-Long Lin et al. BIOMEDICINE & PHARMACOTHERAPY
- PCSK9 inhibition in the management of familial hypercholesterolemia
- (2018) Masatsune Ogura Journal of Cardiology
- Inclisiran Lowers LDL-C and PCSK9 Irrespective of Diabetes Status: The ORION-1 Randomized Clinical Trial
- (2018) Lawrence A. Leiter et al. DIABETES CARE
- Safety and efficacy of statin therapy
- (2018) Bhavin B. Adhyaru et al. Nature Reviews Cardiology
- Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
- (2018) Gregory G. Schwartz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Patient adherence, compliance, and perspectives on evolocumab for the management of resistant hypercholesterolemia
- (2018) Constantine E. Kosmas et al. Patient Preference and Adherence
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
- (2017) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Highly Durable RNAi Therapeutic Inhibitor of PCSK9
- (2017) Kevin Fitzgerald et al. NEW ENGLAND JOURNAL OF MEDICINE
- Limitations of cholesterol lowering with PCSK9 inhibitors
- (2017) Gilbert Thompson Lancet Diabetes & Endocrinology
- Familial Hypercholesterolemia—Epidemiology, Diagnosis, and Screening
- (2015) Siddharth Singh et al. Current Atherosclerosis Reports
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started